Short answer
Alnylam Pharmaceuticals (ALNY) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
Alnylam Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full earnings release in Exhibit 99.1, the key source for revenue, profitability and guidance details
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1.46B, up 17%, led by net product revenue $1.29B, up 52%, reinforcing commercial momentum
- AMVUTTRA revenue $1.13B, up 65%, while ONPATTRO fell 50% to $20M, signaling portfolio migration toward newer therapy
- GAAP net income $2.17B benefited primarily from a $1.9B deferred-tax valuation allowance release, limiting earnings quality
- TRITON-CM enrollment target raised from 1,750 to approximately 2,250 patients, with potential nucresiran launch still targeted by 2030
- Brezosiran reduced CSF mutant huntingtin 60%-64% at month 3 in the highest dose group, supporting a pivotal study planned for 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alnylam Pharmaceuticals 8-K filings
Get the next ALNY 8-K as it lands
Follow ALNY for push alerts, or ask the research agent what this filing means.